Tesamorelin 2mg — Vial Spec, Reconstitution Math & COA

Overview of the Tesamorelin 2mg Lyophilized Specification

A 2mg vial of lyophilized Tesamorelin contains exactly 2.0 milligrams of high-purity synthetic growth hormone-releasing hormone (GHRH) analog, formulated as a stable, vacuum-sealed cake. This specific unit mass is frequently requested by research facilities executing short-duration assay series, pilot feasibility studies, or isolated in vitro cell culture treatments where long-term storage of reconstituted solution is undesirable. While PX1 Research standardizes primary inventory on larger formats such as the high-yield Tesamorelin 10mg vial to accommodate high-throughput study protocols, understanding the physical dynamics and mathematical reconstitution of a 2mg vial remains fundamental to laboratory planning.

In a laboratory setting, the 2mg lyophilized unit mass provides a localized working sample that reduces the risk of repeated thermal degradation or prolonged liquid storage. Lyophilization is performed under controlled aseptic conditions using pharmaceutical-grade bulking agents (such as mannitol or trehalose) to ensure micro-structural stability and rapid dissolution upon the introduction of a suitable aqueous diluent. Each vial is sealed under an inert nitrogen headspace to protect the peptide backbone against oxidative cleavage during transit and freezer storage.

Molecular Structure and Biochemical Mechanism of Action

Tesamorelin (CAS No. 218949-48-5) is a trans-3-hexenoic acid derivative of human growth hormone-releasing hormone (GHRH 1-44). The addition of the C-terminal hexenoyl group to the native 44-amino acid sequence significantly enhances its enzymatic resistance against dipeptidyl peptidase-IV (DPP-IV) degradation. Preclinical models indicate that this structural modification extends the metabolic half-life of the peptide relative to native endogenous GHRH, permitting sustained receptor interaction without compromising physiological pulse characteristics.

As a potent GHRH receptor agonist, Tesamorelin selectively binds to the GHRH receptor (GHRHR) located on pituitary somatotrophs. In vitro binding assays demonstrate that receptor activation stimulates the adenylyl cyclase pathway, causing an intracellular increase in cyclic adenosine monophosphate (cAMP). This downstream signaling cascade prompts the transcription and pulsatile release of endogenous growth hormone (GH), which subsequently stimulates hepatic synthesis of insulin-like growth factor 1 (IGF-1). Investigational literature demonstrates that this axis plays a critical role in tissue-repair research, lipid oxidation mechanisms, and cellular metabolic regulation.

Reconstitution Mathematics for a 2mg Lyophilized Mass

Accurate volumetric reconstitution is necessary to establish reliable working concentrations for laboratory dispensing. When diluting a 2mg (2,000 micrograms) vial of Tesamorelin, the total mass remains fixed while the solvent volume defines the final concentration per microliter (µL) or milliliter (mL). Researchers frequently utilize Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Normal Saline (0.9% NaCl) depending on the specific requirements of the downstream assay.

To achieve a primary concentration of 2.0 mg/mL, precisely 1.0 mL of diluent is introduced into the 2mg vial. Under this volumetric ratio, a 100 µL micro-aliquot contains 200 µC (0.2 mg) of active compound. Alternatively, introducing 2.0 mL of diluent lowers the concentration to 1.0 mg/mL (100 µg per 100 µL), which is often optimal for precise micro-pipetting in low-dose animal models. If a 3.0 mL diluent volume is selected, the resulting concentration is approximately 0.667 mg/mL (66.7 µg per 100 µL). To quickly determine precise volumetric ratios for non-standard volumes, laboratory staff should consult our integrated reconstitution calculator.

When injecting the diluent into the vacuum-sealed vial, the liquid should be directed along the glass inner wall rather than directly onto the lyophilized cake. Gentle agitation or slow inversion should be used to complete dissolution; direct vortexing or aggressive shaking must be avoided to prevent mechanical shearing of the peptide chain.

Aliquot Planning and In Vitro Dosing Precision

Reconstituted peptide solutions undergo slow chemical degradation over time, driven by hydrolysis and primary structure oxidation. For protocols extending past a 24-to-48-hour window, establishing a systematic aliquoting strategy immediately following reconstitution is essential. Dividing the initial 2mg solution into single-use micro-centrifuge tubes prevents repeated freeze-thaw cycles, which are known to cause protein aggregation and activity loss.

For example, if an in vitro assay protocol requires 100 µg per culture well, a 2mg vial reconstituted in 2.0 mL of diluent (1.0 mg/mL) can be distributed into twenty 100 µL single-use polypropylene aliquots. These aliquots should be flash-frozen using liquid nitrogen or a dry ice/ethanol bath and stored at -80°C until immediate use. Benchtop exposure to ambient room temperatures should be minimized, and working solutions should be kept on wet ice throughout active laboratory procedures.

Quality Control and Analytical Certificate of Analysis (COA)

Every batch of research material supplied by PX1 Research undergoes stringent analytical testing to confirm compound identity, purity, and safety profile prior to release. Every fill size—whether a specialized 2mg trial format or our primary Tesamorelin 10mg product—is matched to a comprehensive, lot-specific document. Investigators can inspect analytical data directly by visiting our dedicated lot-matched COA database.

Analytical verification relies on High-Performance Liquid Chromatography (HPLC) to establish chemical purity, requiring a minimum benchmark threshold of 99.0%. Mass Spectrometry (MS) is simultaneously conducted to verify the exact molecular weight (4460.1 Da) against theoretical structural profiles. Crucially, because bacterial contamination can alter cellular signaling and invalidate metabolic assays, PX1 Research subjects all lots to Limulus Amebocyte Lysate (LAL) testing to enforce strict endotoxin limits (<0.01 EU/mg). All testing is conducted through an independent, ISO 17025 accredited laboratory.

Storage, Stability, and Handling Protocols

Proper temperature control is required to preserve the structural integrity of Tesamorelin throughout its experimental lifespan. In its unreconstituted, lyophilized state, the 2mg vial should be stored in a commercial freezer at -20°C for short-to-medium term storage, or at -80°C for long-term preservation exceeding six months. Protect the vial from prolonged exposure to ambient light by maintaining original packaging or utilizing amber storage containers.

Once reconstituted with bacteriostatic water, the solution remains stable at refrigerated temperatures (2°C to 8°C) for up to 28 days due to the antimicrobial properties of the benzyl alcohol preservative. If reconstituted with unpreserved sterile water or saline, the solution must be used within 24 hours or immediately aliquoted and frozen. Reconstituted solutions should never be stored in frost-free freezers, as cyclic temperature fluctuations induce micro-thawing and rapid peptide breakdown.

Comparative Analysis: GHRH Analogs and Growth Factor Secretagogues

When designing preclinical growth factor release experiments, researchers often compare Tesamorelin against alternative secretagogues to select the appropriate candidate for their target physiological system. Tesamorelin is distinct due to its hexenoyl modification and high specificity for GHRH receptors, resulting in sustained GH output without significantly elevating baseline cortisol or prolactin levels in animal models.

For instance, CJC-1295 No DAC (also known as Modified GRF 1-29) offers a shorter plasma half-life compared to Tesamorelin, making it ideal for studies requiring brief, acute GHRH stimulation. Conversely, first-generation analogs like Sermorelin consist of only the first 29 amino acids of endogenous GHRH and are subject to faster enzymatic cleavage by DPP-IV. When evaluating ghrelin-receptor agonists rather than GHRH analogs, compounds such as Ipamorelin target the Growth Hormone Secretagogue Receptor (GHSR-1a), offering a complementary mechanism that can be studied independently or in combination with GHRH agonists in laboratory settings.

Evaluating Format Selection: Single 2mg Vial vs. High-Yield Bulk Sizes

Selecting the appropriate vial size depends directly on experimental design, assay volume, and budget efficiency. The 2mg vial format is specifically suited for low-volume feasibility testing, single-assay validation runs, or laboratories operating with strict limits on active wet storage. It eliminates unnecessary mass accumulation when a project requires minimal compound.

However, for high-throughput screening, multi-animal cohorts, or long-term chronic research protocols, larger mass configurations offer superior cost-per-milligram efficiency and reduced lot-to-lot variable risk. Researchers requiring larger quantities are encouraged to explore our complete catalog of research peptides or register for wholesale lab accounts to obtain larger bulk configurations, including our core 10mg Tesamorelin offerings. Reviewing overall protocol duration prior to order placement ensures optimal balance between reagent freshness and unit economics.

Preclinical Applications in Metabolic and Tissue-Repair Research

Preclinical data suggest that Tesamorelin acts as a powerful regulator of peripheral lipid metabolism and tissue turnover. In rodent models of metabolic dysfunction and hepatic steatosis, administration of GHRH analogs has been observed to accelerate beta-oxidation pathways, reduce visceral adipose tissue volume, and improve triglyceride processing. These effects are mediated both directly through GH-receptor activation on adipocytes and indirectly via hepatic IGF-1 release.

In tissue-repair models, elevated systemic and localized IGF-1 levels downstream of GHRH stimulation correlate with increased fibroblast proliferation, enhanced collagen deposition, and accelerated cellular migration. In vitro assays using skeletal muscle progenitor cells indicate that exposure to Tesamorelin-stimulated media promotes protein synthesis and satellite cell activation. Further information on ongoing study designs and published literature can be explored through our dedicated peptide research hub.